HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IDN 5390

structure in first source

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - Taxoids: 2650
        IDN 5390: 5
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclodecanes
        Taxoids: 2650
        IDN 5390: 5
    - Bridged-Ring Compounds: 1
      - IDN 5390: 5
Polycyclic Compounds: 6
- Bridged-Ring Compounds: 1
  - IDN 5390: 5

Experts

1.	D'Incalci, M: 2 articles (12/2006 - 03/2003)
2.	Frapolli, R: 2 articles (12/2006 - 03/2003)
3.	Morazzoni, P: 2 articles (12/2006 - 03/2003)
4.	Zucchetti, M: 2 articles (12/2006 - 03/2003)
5.	Cassinelli, G: 2 articles (04/2004 - 03/2003)
6.	Lanzi, C: 2 articles (04/2004 - 03/2003)
7.	Pratesi, G: 2 articles (04/2004 - 03/2003)
8.	Supino, R: 2 articles (04/2004 - 03/2003)
9.	Zunino, F: 2 articles (04/2004 - 03/2003)
10.	Giavazzi, Raffaella: 2 articles (04/2003 - 04/2002)

Related Diseases

1.	Carcinoma (Carcinomatosis) 03/24/2003 - "The aim of the study was to investigate the preclinical pharmacologic profile of IDN 5390 in a variety of human tumour xenografts, including ovarian and colon carcinoma and a glioblastoma. " 04/05/2004 - "The aim of the study was to investigate the antitumour and antiangiogenic potential of oral IDN 5390 on a human ovarian carcinoma xenograft, the INT.ACP/PTX, resistant to paclitaxel (PTX). "
2.	Neoplasms (Cancer) 04/01/2003 - "Preclinical studies indicate that, in vivo, oral IDN 5390 has a favorable bioavailability, is well tolerated and shows a significant anti-neoplastic activity on a panel of different tumor models, including paclitaxel-resistant tumors. " 12/01/2006 - "Four metabolites were found in plasma at detectable levels; one of them, with restored taxane scaffold, is a species 3 times more potent than IDN 5390, possibly contributing to the observed anti-tumor activity." 12/01/2006 - "In vivo, IDN 5390 shows activity against paclitaxel-sensitive and -resistant tumors when administered on a prolonged, continuous dosage schedule. " 12/01/2006 - "Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors."
3.	Glioblastoma (Glioblastoma Multiforme) 03/24/2003 - "The aim of the study was to investigate the preclinical pharmacologic profile of IDN 5390 in a variety of human tumour xenografts, including ovarian and colon carcinoma and a glioblastoma. "
4.	Neoplasm Micrometastasis 04/01/2002 - "Daily treatment with IDN 5390 in mice bearing established lung micrometastases from the B16BL6 murine melanoma caused a reduction in the size of metastases. "
5.	Neoplasm Metastasis (Metastasis) 04/01/2002 - "Daily treatment with IDN 5390 in mice bearing established lung micrometastases from the B16BL6 murine melanoma caused a reduction in the size of metastases. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	taxane